Mitsubishi UFJ Trust & Banking Corp Has $2.68 Million Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Mitsubishi UFJ Trust & Banking Corp decreased its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 14.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 8,161 shares of the medical research company’s stock after selling 1,416 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp’s holdings in Bio-Rad Laboratories were worth $2,681,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in BIO. Venturi Wealth Management LLC lifted its position in Bio-Rad Laboratories by 2,175.0% during the 4th quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company’s stock worth $30,000 after buying an additional 87 shares in the last quarter. Picton Mahoney Asset Management raised its holdings in Bio-Rad Laboratories by 55.6% during the fourth quarter. Picton Mahoney Asset Management now owns 98 shares of the medical research company’s stock worth $32,000 after acquiring an additional 35 shares in the last quarter. Asset Planning Inc bought a new position in Bio-Rad Laboratories in the fourth quarter valued at approximately $33,000. UMB Bank n.a. increased its position in shares of Bio-Rad Laboratories by 41.6% during the 4th quarter. UMB Bank n.a. now owns 109 shares of the medical research company’s stock worth $36,000 after purchasing an additional 32 shares during the last quarter. Finally, Cape Investment Advisory Inc. bought a new stake in shares of Bio-Rad Laboratories during the 4th quarter worth approximately $38,000. Institutional investors own 65.24% of the company’s stock.

Analysts Set New Price Targets

BIO has been the subject of several analyst reports. Wells Fargo & Company decreased their target price on shares of Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 12th. Royal Bank of Canada reissued an “outperform” rating and issued a $481.00 price objective on shares of Bio-Rad Laboratories in a research report on Tuesday, January 14th. Finally, StockNews.com cut shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Monday, February 17th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, Bio-Rad Laboratories currently has an average rating of “Moderate Buy” and a consensus price target of $395.20.

Bio-Rad Laboratories Stock Performance

NYSE BIO opened at $244.29 on Tuesday. Bio-Rad Laboratories, Inc. has a 52-week low of $235.84 and a 52-week high of $387.99. The stock has a market cap of $6.84 billion, a PE ratio of -3.76 and a beta of 0.98. The firm has a 50-day moving average of $291.56 and a 200-day moving average of $321.95. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.85 and a current ratio of 6.48.

Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings data on Thursday, February 13th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. On average, sell-side analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.